Help!
I need philanthropists to help Impetus Grants produce the missing data AI needs to ACTUALLY cure diseases of aging.
There’s a lot of talk about simulation solving biology. Useful simulations don’t come out of thin air: DeepMind’s latest weather prediction model was trained on weather records dating back to 1959. AlphaFold had decades of PDB. Tesla and Waymo’s driving simulations draw on data collected over tens of millions of miles on real roads.
Building the biological equivalent requires a much stronger data foundation. We need more observations of how diseases with long timelines like Alzheimer’s unfold and respond to treatments. Some of those observations will take years no matter how fast intelligence improves. So I’m directing @impetusgrants to identify longitudinal biosamples we can use for AI-quality data generation, as well as starting necessary new cohorts today.
I started @impetusgrants in 2021 after hearing @patrickc talk about Fast Grants at a conference. If fast grants worked for COVID, why not longevity? COVID was obviously urgent. But far more people die from age-related diseases.
Since then we’ve deployed $34M across 146 projects and supported five clinical trials, with resulting publications 100x representation in Nature/Science/Cell About 60% of the papers we assessed had no National Institute on Aging support identified. Very satisfying to see work we funded a few years ago now bearing fruit: https://t.co/AUflHFtZEA
The next round will fund around 50 projects generating open source data on how diseases of aging develop and respond to treatments. We’ve raised >$9M toward the $15M we need to kick off.
If you’d like to help fund this or know someone who could, please DM me.
(No fancy video of rockets and art deco, all our money goes to longevity research)
Our paper is out in @NatureAging. We looked for factors that make old cells' gene expression young without erasing their identity. SRSF1 came out as a promising rejuvenation target that reduced aging hallmarks in human cells and extended median lifespan of aged mice by 14%.
1/4
Today we announced interim data from our first-in-human, Phase 1 clinical trial evaluating our lead program in optic neuropathies, showing it was well-tolerated by 3 participants with glaucoma.
Read more about our safety & visual field observations here:https://t.co/GEYpZl1PN2
1/ Excited to share our new preprint from a joint collaboration between @JswLab + @Bruce_Ksander!
Aging is marked by a progressive loss of resilience to stress. Can we systematically search the human ORFome for genes that make vulnerable cells more resilient?
Performing such a genome-scale ORF screen led us to NKX2-5—a heart transcription factor we engineered to restore vision, and improve health in aged mice.
A breakdown🧵
🔗 https://t.co/WVIO7JOx3p
It takes two (transcription factors) to tango
Transcription factor collaboration enables precise T cell state engineering
https://t.co/UpHTANSeHD
Excited to share our preprint with @JD_Buenrostro, @cgersbach, and an incredible team of collaborators as part of @IGVFConsortium
🧵
Excited to share my postdoc work with @JD_Buenrostro now out in @Nature!
"Epigenetic memory of colitis promotes tumour growth"
https://t.co/6703aeQlLG
We wanted to understand how transient inflammation can create a long-lived increase in cancer risk, even after full recovery 🧵
First test of partial epigenetic reprogramming to reverse aging for two eye conditions (glaucoma and NAION) gets FDA go ahead
@lifebiosciences Based on 2020 @Nature paper https://t.co/7au101MazD
https://t.co/NAZCrVIz4V
Huge thanks to all co-authors and the inimitable
@JD_Buenrostro for supporting this new direction - I got to think about evolution, engineering, chromatin biophysics, and modeling during the course of this project. For more, check out the preprint: https://t.co/hMVuYLDZ3Y
Excited to share a short article I wrote describing: Slide-tags - which enables spatial single-nucleus sequencing, allowing us to dive deeper into the complexity of tissue organization. Grateful for the amazing team and support from @insitubiology and @macosko! #ToolsOfTheTrade
The latest LLLM (large language of life) foundation model, with state-of-the art chronological age estimation, prediction of outcomes, and performance across different datasets and conditions
Introducing IN SITU GENOME SEQUENCING, a new technology to resolve DNA sequence🧬 and structure🔬
A team effort with @Andrew_C_Payne, @PaulReginato, @eboyden3, @JD_Buenrostro, and Fei Chen
https://t.co/2EcxBneYDn
This is how it works: (1/8)
Thrilled to see our ExIGS tool featured! A true testament to the power of collaboration. Huge congrats to the team for their hard work! 🧬@ajaylabade31@z_chiang@CarolineComenho https://t.co/x6e5P3MfeW
T cells become exhausted and fail to control tumors in cancer patients. What if we could replicate T cell exhaustion in vitro and uncover the gene regulatory network driving exhaustion, enabling immuno-oncology drug discovery? With AstraZeneca, the Buenrostro lab addresses this gap (https://t.co/BRC1tAHaWU):
We are recruiting postdoctoral fellows in neurobiology and development to complement our group specializing in genomic technologies, epigenetics and machine learning. projects are very well funded and we are interested in co-mentorship. Please DM if interested in hearing more!
Our latest paper is out - a new method called "TIME-Seq" to measure biological age for just a few dollars. Great work Patrick Griffin! @NatureAging Free download https://t.co/mXp6hNDCuO
Can we reverse aging?
7 yrs ago, Ocampo et al. showed that partial reprogramming can ameliorate aging hallmarks. But, OSKM induction has safety limitations & no new factors have emerged since. Here, https://t.co/7ZXhqHYDAD we used 🧬 screens to find new rejuvenation factors🧵1/8